ArticleVaccines2025
Outer Membrane Proteins as Vaccine Targets Against
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Design and functional characterization of recombinant chimeras as vaccine candidates against Lawsonia intracellularis.Biotechnology letters · 2026Article
- Article
- A low-endotoxic Salmonella vector with dual bacterial-host promoter expression of Lawsonia intracellularis antigens elicits protective immunity in a murine model.Veterinary research · 2026Article
- Porcine proliferative enteropathy: overview of disease dynamics and non-antibiotic alternatives for prevention and control strategies.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
background
aimTo evaluate the effectiveness of two novel subunit vaccines targeting outer membrane proteins on LI.
methodsThe two vaccines included OMP2c.cVLP, where the OMP2c antigen was anchored on the surface of capsid virus-like particles (cVLP); and MBP.INVASc, where antigens were anchored to an MBP fusion protein. Groups of six mice, as proof of concept, and six piglets were immunized with either OMP2c.cVLP, MBP.INVASc., or PBS as a control using a prime-boost regime.
resultsBoth OMP2c.cVLP and MBP.INVASc subunit vaccines induced strong antigen-specific serum IgG and IgA responses. There were no significant differences in weight gain among the groups. Mild-to-moderate clinical signs of LI infection were observed, but vaccinated groups showed lower inflammatory scores and fewer animals tested positive for bacteria by immunohistochemistry. Although neither vaccine completely prevented clinical signs of LI infection, both effectively reduced inflammation and lowered the pathogen load, thereby mitigating the severity of the disease, particularly the MBP.INVASc vaccine.
conclusionsThese findings suggest that both vaccines have the potential for further development and optimization to enhance their protective efficacy against LI infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.